Canaccord Genuity Reiterates a 'Buy' on AcelRx Pharmaceuticals (ACRX); ARX-01's Phase 3 Study to Commence by Q4 in H1/12
Tweet
Share
E-mailGet Alerts ACRX Hot Sheet
Price: $0.86 --0%
Rating Summary:
10 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 10 | New: 5
Rating Summary:
10 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 10 | New: 5
Join SI Premium – FREE
Canaccord Genuity Reiterates a 'Buy' on AcelRx Pharmaceuticals (NASDAQ: ACRX) price target of $6.00.
Canaccord analyst, Ritu Baral, said, "Reiterate rating and price target on lead candidate ARX--01’s chance of success in patient--controlled post--operative analgesia. ARX-01 is AcelRx’s transmucosal sufentanil-based drug-device combotherapy for patient-controlled post-operative analgesia. We think ARX-01’s two upcoming Phase 3 trials (one versus placebo and one versus current gold standard IV PCA comparator) will yield positive data in mid-2012. AcelRx also has a pipeline of drug-device combination pain relief therapies that are created around the core NanoTab sulfentanil formulation."
For more ratings news on AcelRx Pharmaceuticals click here and for the rating history of AcelRx Pharmaceuticals click here.
Shares of AcelRx Pharmaceuticals closed at $3.70 yesterday.
Canaccord analyst, Ritu Baral, said, "Reiterate rating and price target on lead candidate ARX--01’s chance of success in patient--controlled post--operative analgesia. ARX-01 is AcelRx’s transmucosal sufentanil-based drug-device combotherapy for patient-controlled post-operative analgesia. We think ARX-01’s two upcoming Phase 3 trials (one versus placebo and one versus current gold standard IV PCA comparator) will yield positive data in mid-2012. AcelRx also has a pipeline of drug-device combination pain relief therapies that are created around the core NanoTab sulfentanil formulation."
For more ratings news on AcelRx Pharmaceuticals click here and for the rating history of AcelRx Pharmaceuticals click here.
Shares of AcelRx Pharmaceuticals closed at $3.70 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lam Research (LRCX) PT Lowered to $850 at Susquehanna
- Meta Platforms Inc. (META) PT Lowered to $500 at Baird
- Sherwin-Williams (SHW) PT Lowered to $370 at RBC Capital
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
